Phase III results put obinutuzumab in line for approval ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Autoimmune disease hair loss can happen with alopecia areata, lupus, thyroid diseases, rheumatoid arthritis, Crohn’s disease, and scalp psoriasis. Each disease has different effects, ...

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

Johnson & Johnson has won U.S. Food and Drug Administration fast-track designation for its investigational nipocalimab drug in adults with systemic lupus erythematosus, a chronic autoimmune disease.

New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, ...

Acute kidney injury (AKI) in patients with lupus nephritis is tied with rapid disease worsening and potential progression to chronic kidney disease and kidney failure.

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death, and a glycoengineered Fc region, for higher ...